CAPTRUST Financial Advisors
TRIB

CAPTRUST Financial Advisors’s Trinity Biotech TRIB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,247
Closed -$28.3K – 2815
2025
Q3 		$28.3K Buy
+27,247
New +$28.6K ﹤0.01% 2590

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAPTRUST Financial Advisors's TRIB Position: Q4 2025 in Review

CAPTRUST Financial Advisors sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 27,247 shares — an estimated $28.3K sold.

CAPTRUST Financial Advisors first reported a position in TRIB in Q3 2025 and held it in 1 quarter. The position peaked at $28.3K in Q3 2025. 27 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • CAPTRUST Financial Advisors reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 27,247 Trinity Biotech shares in Q4 2025, an estimated $28.3K.
  • CAPTRUST Financial Advisors first reported a position in Trinity Biotech in Q3 2025 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Trinity Biotech position peaked at $28.3K in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.